---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-028323"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:30:45.760875+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvalent reports Q4 net loss $74.8M, cash $1.1B; pivotal data on track for 2025

## Summary
- Net loss $74.8M (Q4 2024) and $260.8M (FY 2024); cash & equivalents $1.1B, expected to fund into 2028.
- Pivotal data for zidesamtinib in TKI pre-treated ROS1+ NSCLC expected H1 2025; NDA submission mid-2025.
- Pivotal data for neladalkib in TKI pre-treated ALK+ NSCLC expected year-end 2025; Phase 3 ALKAZAR initiating H1 2025.
- Global Expanded Access Programs launched for zidesamtinib and neladalkib for eligible patients.
- Appointed Grant Bogle, former Epizyme CEO, to Board of Directors in December 2024.

## SEC filing metadata
- accession: 0000950170-25-028323
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000095017025028323/0000950170-25-028323-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000095017025028323/nuvl-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-028323
- JSON: https://secwatch.observer/filing/0000950170-25-028323.json
- Plain text: https://secwatch.observer/filing/0000950170-25-028323.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.